NCT06947499View on ClinicalTrials.gov

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

1,186

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2027

Conditions
DiphtheriaTetanusPertussisHepatitis BPoliomyelitisHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

LBVD

Intramuscular injection into the anterolateral area of the thigh

BIOLOGICAL

Pentavalent vaccine and Inactivated Polio vaccine

Intramuscular injection into the anterolateral area of the thigh

Trial Locations (1)

Unknown

RECRUITING

Care CT Group, Dasmariñas

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT06947499 - A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series | Biotech Hunter | Biotech Hunter